InflaRx GmbH

Industry · 12 registered clinical trials.

Status	Trial	Phase	Started
Terminated	Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticar Chronic Urticaria, Idiopathic, Hidradenitis, Hidradenitis Suppurativa	Phase 2	2025-01-02
Terminated	Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum Pyoderma Gangrenosum	Phase 3	2023-11-01
Terminated	Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cS SCC - Squamous Cell Carcinoma of Skin	Phase 2	2021-03-31
Completed	Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia Severe COVID-19 Pneumonia	Phase 2 / Phase 3	2020-03-31
Completed	Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum Pyoderma Gangrenosum	Phase 2	2019-05-16
Completed	Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangii Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)	Phase 2	2019-04-03
Terminated	Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)	Phase 2	2018-10-15
Completed	Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) Hidradenitis Suppurativa (HS)	Phase 2	2018-02-26
Completed	Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa Hidradenitis Suppurativa	Phase 2	2016-12-01
Completed	Studying Complement Inhibition in Complex Cardiac Surgery Systemic Inflammatory Response Syndrome, C.Surgical Procedure; Cardiac	Phase 2	2016-05-01
Completed	Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction Severe Sepsis, Septic Shock	Phase 2	2014-04-01
Completed	Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29 Drug Safety	Phase 1	2011-03-01